ERYtech Pharma Announces Oral Presentations Of GRASPA Phase III Results At ASCO And EHA Annual Meetings
LYON, France--(BUSINESS WIRE)--Regulatory News:
ERYTECH Pharma (Paris:ERYP) (ADR:EYRYY) (Euronext Paris - ERYP; OTC US - EYRYY), the French biopharmaceutical company that develops innovative ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical needs, announces that the data related to GRASPA® Phase 3 pivotal program in Acute Lymphoblastic Leukemia (ALL) will be the subject of oral presentations at the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO), May 29 - June 2, Chicago, USA, and at the 20th Congress of European Hematology, June 11 - 14, Vienna, Austria. A poster on the design of the ongoing Phase IIb study in Acute Myeloid Leukemia (AML) will also be presented at ASCO.
Help employers find you! Check out all the jobs and post your resume.
ERYTECH Pharma (Paris:ERYP) (ADR:EYRYY) (Euronext Paris - ERYP; OTC US - EYRYY), the French biopharmaceutical company that develops innovative ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical needs, announces that the data related to GRASPA® Phase 3 pivotal program in Acute Lymphoblastic Leukemia (ALL) will be the subject of oral presentations at the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO), May 29 - June 2, Chicago, USA, and at the 20th Congress of European Hematology, June 11 - 14, Vienna, Austria. A poster on the design of the ongoing Phase IIb study in Acute Myeloid Leukemia (AML) will also be presented at ASCO.
Help employers find you! Check out all the jobs and post your resume.